GLENMARK PHARMACEUTICALS
Back to Balance Sheet
|
GLENMARK PHARMACEUTICALS Last 5 Year Contingent Liabilities History
[Consolidated]
Mar2024 | Mar2023 | Mar2022 | Mar2021 | Mar2020 | |
---|---|---|---|---|---|
Contingent Liabilities | ₹1,063 Cr | ₹337 Cr | ₹361 Cr | ₹384 Cr | ₹271 Cr |
What is the latest Contingent Liabilities ratio of GLENMARK PHARMACEUTICALS ?
Year | Contingent Liabilities |
---|---|
Mar2024 | ₹1,063 Cr |
Mar2023 | ₹337 Cr |
Mar2022 | ₹361 Cr |
Mar2021 | ₹384 Cr |
Mar2020 | ₹271 Cr |
How is Contingent Liabilities of GLENMARK PHARMACEUTICALS Trending?
Years | Contingent Liabilities | % Change | |
---|---|---|---|
Mar2024 | ₹1,063 Cr | 215.81 | |
Mar2023 | ₹337 Cr | -6.81 | |
Mar2022 | ₹361 Cr | -5.96 | |
Mar2021 | ₹384 Cr | 41.66 | |
Mar2020 | ₹271 Cr | - |
Compare Contingent Liabilities of peers of GLENMARK PHARMACEUTICALS
Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
GLENMARK PHARMACEUTICALS | ₹62,844.5 Cr | 21.3% | 32.9% | 58.2% | Stock Analytics | |
SUN PHARMACEUTICAL INDUSTRIES | ₹414,533.0 Cr | 0.6% | -0.4% | 4.7% | Stock Analytics | |
DIVIS LABORATORIES | ₹180,215.0 Cr | -2.2% | 1.7% | 47.3% | Stock Analytics | |
CIPLA | ₹120,428.0 Cr | -0.2% | -1.4% | -1.9% | Stock Analytics | |
TORRENT PHARMACEUTICALS | ₹116,410.0 Cr | 2.5% | 4.8% | 12.2% | Stock Analytics | |
DR REDDYS LABORATORIES | ₹105,253.0 Cr | -2.6% | -8.1% | -4.9% | Stock Analytics |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
GLENMARK PHARMACEUTICALS | 21.3% |
32.9% |
58.2% |
SENSEX | -1.4% |
1.8% |
3.3% |
You may also like the below Video Courses